Strategic Update & Entitlement Offer Presentation

The Board of Directors at Emyria warmly invites you to participate in our upcoming Rights Issue.

This Capital Raising effort, targeting up to $3.1 million, will help fast-track Emyria's mental healthcare programs, including MDMA-assisted therapy for PTSD, novel drug development, and payer engagement, while also supporting potential revenue growth and data collection. Every Eligible Shareholder holding Emyria shares by the Record Date (Wednesday, 13th September, 2023) can contribute to Emyria's growth and is welcome to apply for shares priced at $0.075 per new fully paid ordinary share. This presents an opportunity for shareholders to be an integral part of Emyria's development journey.

For more information please head to www.offer.emyria.com